A Phase II Study of GSK2118436 in Patients with Advanced Non-Small Cell Lung Cancer and BRAF Mutations

Protocol
11-023
Full Title
A Phase II Study of the BRAF Inhibitor Dabrafenib as A Single Agent and in Combination with the MEK Inhibitor Trametinib in Subjects with BRAF V600E Mutation Positive Metastatic (stage IV) Non-Small Cell Lung Cancer
Phase
II
Purpose

BRAF is a protein that, when mutated, can promote the development and growth of certain cancers. GSK2118436 is an investigational drug designed to inhibit cancer growth by interfering with the activity of mutated BRAF.

In this study, researchers are evaluating the safety and effectiveness of GSK2118436 in patients with advanced non-small cell lung cancer who have mutated BRAF and whose disease continues to grow despite prior therapy. GSK2118436 is a capsule that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have stage IV NSCLC that continues to grow despite at least one prior regimen of chemotherapy for advanced disease.
  • Patients’ tumors must contain a documented V600E mutation in BRAF.
  • At least 4 weeks must have passed since the completion of prior therapy and entry into the study. Patients who have had prior treatment with a BRAF or MEK inhibitor may not participate.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Gregory Riely at 646-888-4199.

Disease(s)
Lung Cancer
Lung Cancer, Non-Small Cell
Lung Cancer, Non-Small Cell: Lung Adenocarcinoma
Locations
Related Diseases